[Pharmacotherapy of endothelial dysfunction in patients with atherosclerotic brain ischemia]

Area of Science:

• Neurology
• Vascular Biology
• Pharmacology

Background:

• Chronic cerebral ischemia (CCI) stage III is characterized by impaired endothelial function.
• Endothelial dysfunction contributes to the progression of cerebrovascular diseases like atherosclerosis.
• Pharmacological interventions aim to restore vascular health and improve outcomes in CCI patients.

Purpose of the Study:

• To evaluate the efficacy of deproteinized hemoderivative of calf blood, thioctic acid, vinpocetine, and piracetam in improving endothelial function in patients with CCI stage III.
• To compare the effects of these agents on both large and small blood vessel properties.

Main Methods:

• A study involving patients diagnosed with chronic cerebral ischemia stage III.
• Pharmacological treatment utilizing deproteinized hemoderivative of calf blood, thioctic acid, vinpocetine, and piracetam.
• Assessment of endothelial function through various vascular parameters, including the index of occlusion and phase shift.

Main Results:

• Significant improvement in endothelial properties of both large and small blood vessels was observed post-treatment.
• The index of occlusion, reflecting small vessel function, reached normal values.
• Phase shift values did not fully normalize, indicating differential impact on vessel sizes.

Conclusions:

• Deproteinized hemoderivative of calf blood and thioctic acid demonstrated the most significant efficacy in correcting endothelial dysfunction in CCI stage III.
• Cerebral atherosclerosis affects small arteries to a lesser extent initially compared to large and medium-caliber arteries.
• These findings support the use of specific pharmacological agents for managing endothelial dysfunction in chronic cerebral ischemia.